Citi Pharma Ltd. (CPHL) announcements
Everything Citi Pharma Ltd. has filed with the Pakistan Stock Exchange, newest first: financial results, insider trades, material information and notices.
- NoticeTransmission of Quarterly Report for the Period Ended 30 September 2026
- Financial resultCiti Pharma Limited reported a net profit of Rs 233.23 million for the period ended September 30, 2026Filed as: Financial Results for the Quarter Ended 30 September 2026
- NoticeBoard Meeting In Progress
- Material informationCiti Pharma Acquires 20% of Pakheim InternationalCiti Pharma Limited acquires 20% shareholding in Pakheim International Pharma, marking the first step towards full acquisition.
- NoticeCertified true copy of the resolutions passed in the Annual General Meeting of the Company
- NoticeChange of Chief Financial Officer
- NoticeBoard Meeting
- Material informationCiti Pharma Acquires Pakheim InternationalCiti Pharma receives CCP authorization for 100% acquisition of Pakheim International Pharma. Strategic move to enhance market position.
- NoticeTransmission of Annual Report for the Year Ended 30 June 2026
- NoticeNotice of Annual General Meeting - Post Publication
- NoticeNotice of Annual General Meeting (Prior to Publication)
- NoticeBoard Meeting
- NoticeCertified Copy of the Resolutions Adopted in the Extraordinary General Meeting held on 18 September 2026
- NoticeNotice of Extraordinary General Meeting
- Insider tradeExecutive Director Rizwan Ahmad bought 2,000,000 shares at Rs 74.66, increasing cumulative holding to 56,029,752 shares (24.52%)Filed as: Insider Transaction
- NoticeChief Financial Officer
- NoticeCertified Copy of the Resolutions Adopted in the Extraordinary General Meeting held on 08 July 2026
- Material informationCiti Pharma Announces Demerger SchemeCiti Pharma's board approves demerger scheme transferring properties to Citi Core Holdings, pending shareholder and court approvals.
- NoticeBoard Meeting Other Than Financial Results
- NoticeNotice of Extraordinary General Meeting
- Material informationStrategic Partnership with JS Global AnnouncedCiti Pharma signs Strategic Financial Advisory Agreement with JS Global to explore investment banking and capital market opportunities.
- Material informationCiti Pharma Expands with Pakheim AcquisitionCiti Pharma acquires Pakheim to boost manufacturing and market presence, targeting Rs 5B revenue in five years.
- Financial resultCiti Pharma Limited reported a net profit of Rs 883 million for the nine months ended March 31, 2026Filed as: Financial Results for the Quarter Ended 31 March 2026
- Insider tradeExecutive Director Rizwan Ahmad bought 100,000 shares at Rs 79.77, increasing cumulative holding to 54,029,752 shares (23.65%)Filed as: Insider Transaction
- Insider tradeNon-Executive Director Nadeem Amjad sold 2,000,000 shares at Rs 85.50, reducing cumulative holding to 22,106,895 shares (9.67%)Filed as: Insider Transaction
- Insider tradeNon-Executive Director Muhammad Naeem executed multiple transactions, selling 1,717,000 shares and buying 404Filed as: Insider Transaction
- Insider tradeMuhammad Naeem (Non-Executive Director) bought 800,000 shares at Rs 86.58Filed as: Insider Transaction
- Insider tradeMuhammad Naeem (Non-Executive Director) bought 500,000 shares at Rs 84.56Filed as: Insider Transaction
- Insider tradeMuhammad Naeem (Non-Executive Director) bought 902,000 shares at Rs 84.30Filed as: Insider Transaction
- Insider tradeNadeem Amjad (Non-Executive Director) sold 402,000 shares at Rs 83.25Filed as: Insider Transaction
- Insider tradeSaira Aslam (Non-Executive Director) bought 10,000 shares at Rs 73.45Filed as: Insider Transaction
- Insider tradeSaira Aslam (Non-Executive Director) bought 50,000 shares at Rs 72.88Filed as: Insider Transaction
- Insider tradeSaira Aslam (Non-Executive Director) bought 60,000 shares at Rs 89.00Filed as: Insider Transaction
- Insider tradeSaira Aslam (Non-Executive Director) sold 417,500 shares at Rs 91.00Filed as: Insider Transaction
- Insider tradeSaira Aslam (Non-Executive Director) sold 82,500 shares at Rs 87.68Filed as: Insider Transaction
- Insider tradeSaira Aslam (Non-Executive Director) bought 500,000 shares at Rs 91.08Filed as: Insider Transaction
- Insider tradeNadeem Amjad (Non-Executive Director) sold 222,421 shares at Rs 75.73Filed as: Insider Transaction
- Insider tradeSaira Aslam (Non-Executive Director) bought 141,375 shares at Rs 77.92Filed as: Insider Transaction
- Insider tradeSaira Aslam (Non-Executive Director) bought 60,000 shares at Rs 89.10Filed as: Insider Transaction
- Material informationCiti Pharma Announces PKR 2B IPO for ExpansionCiti Pharma plans a Rs 2B IPO for its new veterinary subsidiary, aiming for Rs 1.5B revenue in FY26.
- Insider tradeSaira Aslam (Non-Executive Director) bought 39,500 shares at Rs 83.20Filed as: Insider Transaction
- Material informationCiti Pharma Expands with PKR 7B Real Estate ProjectsCiti Pharma Limited announces Rs 7B investment in real estate projects across Lahore and Islamabad, with completion expected by 2027.
- Insider tradeRizwan Ahmad (Executive Director) bought 200,000 shares at Rs 85.00Filed as: Insider Transaction
- Insider tradeRizwan Ahmad (Executive Director) bought 1,000,000 shares at Rs 82.63Filed as: Insider Transaction
- Insider tradeRizwan Ahmad (Executive Director) bought 301,876 shares at Rs 87.90Filed as: Insider Transaction
- Insider tradeRizwan Ahmad (Executive Director) bought 123,124 shares at Rs 89.91Filed as: Insider Transaction
- Insider tradeNadeem Amjad (Non-Executive Director) sold 775,000 shares at Rs 90.81Filed as: Insider Transaction
- Insider tradeNadeem Amjad (Non-Executive Director) sold 750,000 shares at Rs 89.21Filed as: Insider Transaction
- Insider tradeRizwan Ahmad (Executive Director) bought 505,000 shares at Rs 87.23Filed as: Insider Transaction
Showing the latest 49. Source: company filings on the Pakistan Stock Exchange. Summaries are written from the filings by software and can contain errors; the filing itself is the record. Investing in securities involves risk, including possible loss of principal.